eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unne...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...
Multi-study collaboration leverages SEQSTER's real world data (RWD) platform to support Praxis's portfolio of precision therapies for CNS disorders ...
AI-enabled brown adipose tissue (BAT) phenotype unlocks population-scale human genetic discovery BAT-01 knockdown drives 15% body-weight reduction in ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...
Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at...
AI's presence in pharma & animal health is rapidly expanding – the global AI pharmaceutical market is expected to grow to tens of billion...
Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps Ge...
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...
CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled da...
2026 is already shaping up to be a historic year for brain health as the healthcare industry confronts an urgent reality: cognitive impairment, Alzheimer...
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss ...
Clinical data from pivotal trial in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits Primary safety endp...
© 2026 Biopharma Boardroom. All Rights Reserved.
